This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Novo Nordisk's Victoza Gets FDA Nod for Pediatric Patients
by Zacks Equity Research
Novo Nordisk's (NVO) Victoza gets FDA approval for the treatment of pediatric patients aged 10 years or older with type II diabetes.
Are You Looking for a High-Growth Dividend Stock? Eli Lilly (LLY) Could Be a Great Choice
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.
Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod
by Kinjel Shah
Key developments of the week include Merck's (MRK) deal to buy Tilos Therapeutics and FDA approval for Roche's (RHHBY) polatuzumab vedotin and Merck's Keytruda.
NuCana's Biliary Tract Cancer Candidate Gets Orphan Drug Tag
by Zacks Equity Research
The FDA confers an orphan drug designation on NuCana's (NCNA) pipeline candidate, Acelarin, for treating patients with biliary tract cancer
Pfizer's (PFE) Xeljanz Effective As Monotherapy in RA Study
by Zacks Equity Research
Pfizer's (PFE) study on JAK inhibitor Xeljanz XR demonstrates the efficacy of the medicine when used as a monotherapy without methotrexate.
Galapagos Ends Enrollment in Osteoarthritis Study Before Time
by Zacks Equity Research
Galapagos (GLPG) closes enrollment in the phase II study on GLPG1972/S201086 for the treatment of patients with osteoarthritis prior to the stipulated date.
Boost Your Portfolio's Health With These 3 Big Drug Stocks
by Kinjel Shah
The large-cap pharma industry is doing well in 2019. Here are three stocks from the space that investors may consider betting on.
The Zacks Analyst Blog Highlights: Oracle, Eli Lilly, Mondelez, Walgreens and Southwest
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Oracle, Eli Lilly, Mondelez, Walgreens and Southwest
Lilly Announces Tradjenta Cardiovascular Outcome Study Data
by Zacks Equity Research
Tradjenta leads to fewer events of hypoglycemia and modest weight reduction in type II diabetes patients compared to Sanofi's Amaryl.
Merck (MRK) to Buy Private Biotech Tilos for Up to $773M
by Zacks Equity Research
Merck (MRK) set to buy private preclinical biotech Tilos Therapeutics in a deal that could be worth up to $773 million
The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AstraZeneca
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AstraZeneca
Lilly (LLY) Presents Data From Diabetes Studies at ADA Meet
by Zacks Equity Research
Lilly (LLY) presents additional data from studies on investigational diabetes products ultra-rapid-acting lispro and tirzepatide and outcomes study (REWIND) on Trulicity at ADA.
Top Analyst Reports for Oracle, Eli Lilly & Mondelez
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Oracle (ORCL), Eli Lilly (LLY) and Mondelez (MDLZ).
Pharma Stock Roundup: ASCO Update, FDA Nod for LLY's Emgality for Cluster Headache
by Kinjel Shah
Pharma bigwigs present data from cancer studies at ASCO. Lilly's (LLY) CGRP Emgality gets FDA approval for episodic cluster headache in adults.
Incyte Begins Phase III Study for Treatment of Duct Cancer
by Zacks Equity Research
Incyte (INCY) begins first phase III study of pemigatinib as a first-line therapy for patients with metastatic or surgically unresectable cholangiocarcinoma.
Lilly's Emgality Gets FDA Approval for Cluster Headache
by Zacks Equity Research
Lilly's (LLY) CGRP antibody, Emgality, becomes the first and only medicine approved to treat episodic cluster headache in adults.
Celldex Presents Data From CDX-3379 Study at ASCO, Stock Down
by Zacks Equity Research
Celldex (CLDX) presents updated data on CDX-3379 and Erbitux combination regimen, which supports further development in biomarker selected patient population.
Why Cancer-Fighting Stocks & ETFs Are Soaring
by Neena Mishra
The cancer immunotherapy ETF is soaring today as some of its holdings presented very promising results at the ASCO conference. Find out more on the podcast.
Merck's Keytruda Improves 5-Year Survival in Lung Cancer
by Zacks Equity Research
Merck (MRK) presents longest follow-up data for Keytruda in advance lung cancer at ASCO 2019. The five-year overall survival rates in the Keytruda arm are better than historical rates
Lilly (LLY) Down 2.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Lilly In-Licenses Private Biotech's Non-Opoid Pain Candidate
by Zacks Equity Research
Lilly (LLY) inks a deal with the privately held Centrexion Therapeutics to add the latter's early-stage pain candidate, CNTX-0290, to its portfolio.
Incyte (INCY) Receives FDA Nod for Label Expansion of Jakafi
by Zacks Equity Research
Incyte (INCY) obtains FDA approval for a third indication of lead drug, Jakafi, for the treatment of GVHD.
Nektar (NKTR) Announces Formation of CNS-Focused Subsidiary
by Zacks Equity Research
Nektar (NKTR) forms wholly-owned subsidiary, Inheris Biopharm, focusing on CNS pipeline. The subsidiary will mainly be responsible for potential commercialization of under review pain drug, NKTR-181.
Pharma Stock Roundup: MRK's Cancer Biotech Buyout, ABBV, LLY's Pipeline Updates
by Kinjel Shah
Key highlights of the week include Merck's (MRK) offer to buy private cancer biotech and AbbVie (ABBV) and Lilly's (LLY) updates from clinical studies.
Earnings Preview: Veeva (VEEV), Palo Alto Networks (PANW), Workday (WDAY)
by Benjamin Rains
Let's look at what investors should expect from some of the more notable tech companies still left to report: Veeva Systems Inc. (VEEV), Workday, Inc. (WDAY), and Palo Alto Networks, Inc. (PANW).